MaRS Innovation Launches New Drug Discovery Program Targeting Rare and Disabling Developmental Disorder
July 15, 2019 07:00 ET | MaRS Innovation
Toronto, ON, July 15, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today that it is partnering with Dr. James Eubanks at the University Health Network (UHN) to develop a new treatment for Rett...
Mental Health is Focus of New High-Potential Anti-Depression Project from MaRS Innovation and the Centre for Addiction and Mental Health
June 11, 2019 07:00 ET | MaRS Innovation
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many...
MaRS Innovation adds to growing portfolio with two new LAB150 projects to create novel therapeutics for Cystic Fibrosis and Respiratory Syncytial Virus.
February 27, 2019 07:00 ET | MaRS Innovation
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific...
MaRS Innovation’s Triphase Accelerator Announces New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
January 29, 2019 08:00 ET | MaRS Innovation
Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the...
Fibrocor, a MaRS Innovation portfolio company, announces deal with Galapagos
January 07, 2019 10:43 ET | MaRS Innovation
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation...
LAB150 awards its second drug discovery project from Canada’s largest research based Hospital, The University Health Network (UHN)
October 04, 2018 08:00 ET | MaRS Innovation
Toronto, ON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec.   The project aims to develop a...
MaRS Innovation appoints Steven Chackowicz as Executive-in-Residence
June 25, 2018 08:00 ET | MaRS Innovation
Toronto, ON, June 25, 2018 (GLOBE NEWSWIRE) -- MaRS innovation (MI) announced today that Steven Chackowicz has been appointed Executive-in-Residence where he will oversee the technology scouting and...
MaRS Innovation Leads Health Innovation Mission to South Korea
April 13, 2018 08:00 ET | MaRS Innovation
Toronto, April 13, 2018 (GLOBE NEWSWIRE) -- Dr. Rafi Hofstein, President and CEO of MaRS Innovation (MI) announced today that as part of Toronto Health Innovation Week, MI will lead a special health...
EVOTEC AG AND MARS INNOVATION ANNOUNCE FIRST FUNDED PROJECT UNDER LAB150 BRIDGE
February 15, 2018 07:00 ET | MaRS Innovation
Hamburg, Germany, and Toronto, Canada, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation announced today that they have...
Schrödinger and MaRS Innovation Announce the Launch of Bright Angel Therapeutics
December 21, 2017 08:00 ET | MaRS Innovation
New York, NY and Toronto Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, and...